B+
Bull case
25%
Probability
Target price
$3.20
+60.8% vs current
PLX
Protalix BiotherapeuticsANYSE American / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$2.20
+10.6% vs current
B-
Bear case
25%
Probability
Target price
$1.10
-44.7% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
+58.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+58.3
Score
AI commentary
This remains a cautious monitoring setup rather than a high-conviction bullish biotech call. Primary evidence improved on May 13, 2026 because the company 8-K and attached release confirmed the earnings print, reaffirmed 2026 guidance, highlighted the $25.0 million Chiesi milestone, and showed $51.1 million of quarter-end cash [#8-K-2026-05-13] [#10-Q-2026-05-13]. But low coverage still matters: checked sources did not show a strong analyst revision wave after the print, consensus data was thin across aggregators, peers remain loose, and by the 2026-05-15 anchor close at $1.98 the packet still did not show a durable post-earnings rerating.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystQ1 milestone-driven beat now has to convert into cleaner underlying commercial demandHigh impact
The May 13, 2026 earnings release showed Q1 revenue of $33.75 million, net income of $18.3 million, and reaffirmed 2026 revenue guidance of $78.0-$83.0 million, but the quarter was heavily boosted by a $25.0 million Chiesi milestone tied to the EU every-4-weeks Elfabrio regimen. The near-term test is whether recurring Elfabrio and Elelyso sales support that outlook rather than another one-time milestone doing most of the work [#8-K-2026-05-13].
2027-03-31catalystStronger cash balance lowers immediate financing pressure but does not remove biotech runway riskHigh impact
Protalix reported $51.1 million of cash, cash equivalents, and short-term bank deposits at March 31, 2026, and said this is sufficient to fund ongoing operations including the Phase 2 RELEASE trial. That is a clear improvement versus year-end, but R&D expense rose 56% year over year to $5.4 million as PRX-115 advanced, so financing sensitivity can return if commercial demand or development timing disappoints [#10-Q-2026-05-13] [#8-K-2026-05-13].
2027-09-30eventPRX-115 Phase 2 execution remains the main pipeline value driverHigh impact
Management said the RELEASE Phase 2 study for PRX-115 continues to enroll and still targets topline results in the second half of 2027. Any meaningful enrollment, protocol, or execution update could matter because the pipeline value case still rests mainly on this program and the visibility remains long-dated [#8-K-2026-05-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology